Pierre Kemula
Director of Finance/CFO chez CUREVAC N.V.
Fortune : 219 175 $ au 31/03/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Ingmar Hoerr | M | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 21 ans |
| Florian von der Muelbe | M | 52 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 24 ans |
| Michael Brosnan | M | 69 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 1 ans |
| Baron Jean Stéphenne | M | 73 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 ans |
| Ulrike Gnad-Vogt | M | - |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 13 ans |
| Friedrich von Bohlen und Halbach | M | 60 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
| Craig Tooman | M | 58 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 5 ans |
| Igor Splawski | M | 56 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 4 ans |
| Bernd Winterhalter | M | 65 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 5 ans |
| Debra Stephanie Barker | M | 61 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 2 ans |
| Sarah Fakih | M | - | - | |
| Timothy M. Wright | M | 69 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 6 ans |
| Mariola Fotin-Mleczek | M | 50 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 18 ans |
| Ralf Clemens | M | 71 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 ans |
| Mathias Hothum | M | 58 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 ans |
| Robert J. W. ten Hoedt | M | 64 | 8 ans | |
| Hans Tanner | M | 72 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 ans |
| Marc M. P. de Garidel | M | 66 | 14 ans | |
| Alexander Zehnder | M | 54 | 1 ans | |
| Carol Xueref | F | 67 | 12 ans | |
| Karine Chevrie | M | - | 9 ans | |
| Jean Stephenne | M | 75 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
| Klaus Schollmeier | M | 67 | 2 ans | |
| Viola Bronsema | M | 61 | 4 ans | |
| Antony Blanc | M | 57 | 4 ans | |
| Malte Greune | M | 59 | 3 ans | |
| Patrick Baumhof | M | - | - | |
| Bettina Jödicke-Braas | F | - | - | |
| Myriam Mendila | M | 58 | 1 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Sonia Benhamida | M | - | 7 ans | |
| Martha Heitzmann-Crawford | M | 56 | 3 ans | |
| Jean-Luc Bélingard | M | 74 | 8 ans | |
| Claire Giraut | F | 67 | 8 ans | |
| David S. Schilansky | M | 48 | 5 ans | |
| James A. Reinstein | M | 59 | - | |
| Siham Imani | F | 47 | 6 ans | |
| Christopher Cozic | M | 46 | 3 ans | |
| Dimitris Voliotis | M | 61 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 1 ans |
| Pierre Boisselier | M | - | 1 ans | |
| Klaus Edvardsen | M | 62 | 1 ans | |
| Heather White | F | - | - | |
| Jean Fabre | M | 65 | 9 ans | |
| Thomas Gidoin | M | 41 | 3 ans | |
| Christophe Vérot | M | 63 | 7 ans | |
| Nathalie Joannes | F | - | 4 ans | |
| Andrew Grethlein | M | 59 | 2 ans | |
| Susheel Surpal | M | - | 3 ans | |
| Claude Bertrand | M | 61 | 8 ans | |
| Franz-Werner Haas | M | 54 | 11 ans | |
| Klaus-Peter Schwabe | M | 82 | - | |
| Alexandre LeBeaut | M | 66 | 6 ans | |
| Daniel L. Menichella | M | 64 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 2 ans |
| Gérard Picot | M | 70 | - | |
| Frédéric Babin | M | - | - | |
| Didier Véron | M | - | 5 ans | |
| Didier Laurens | M | 59 | - | |
| Christel Bories | F | 60 | 3 ans | |
| Richard B. Love | M | 62 | 4 ans | |
| Maïlys Ferrère | F | 60 | 2 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| France | 30 | 50,85% |
| Allemagne | 29 | 49,15% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Pierre Kemula
- Réseau Personnel
